HRP20151148T1 - Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja - Google Patents
Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja Download PDFInfo
- Publication number
- HRP20151148T1 HRP20151148T1 HRP20151148TT HRP20151148T HRP20151148T1 HR P20151148 T1 HRP20151148 T1 HR P20151148T1 HR P20151148T T HRP20151148T T HR P20151148TT HR P20151148 T HRP20151148 T HR P20151148T HR P20151148 T1 HRP20151148 T1 HR P20151148T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- peptide
- use according
- amino acid
- treatment
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000032859 Synucleinopathies Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Najmanje jedan spoj koji sadrži peptid, naznačen time, da taj peptid ima aminokiselinsku sekvencu odabranu iz sljedeće skupine:
CDQPVLPD, CDMPVLPD, CDSPVLPD, CDQPVLPDN, CDMPVLPDN, CDSPVLPDN, CHDRPVTPD, CDRPVTPD, CDVPVLPD, CDTPVYPD, CDTPVIPD, CHDRPVTPDN, CDRPVTPDN, CDVPVLPDN, CDTPVYPDN, CDQPVLPDG, CDMPVLPDG, CDSPVLPDG, CDHPVHPDS, CDMPVSPDR, CDRPVYPDI, CDHPVTPDR, CDTPVLPDS, CDMPVTPDT, CDAPVTPDT, CDSPVVPDN, CDLPVTPDR, CDSPVHPDT, CDAPVRPDS, CDMPVWPDG, CDRPVQPDR, CYDRPVQPDR, CDMPVDADN, DQPVLPDC i DMPVLPDC,
pri čemu se on upotrebljava za prevenciju i/ili liječenje sinukleinopatija.
2. Spoj za uporabu prema zahtjevu 1, naznačen time, da peptid sadrži acetilirani aminokiselinski ostatak ili cistein (C), na svojem N-završetku i/ili na C-završetku.
3. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time, da je sinukleinopatija odabrana iz skupine koju čine poremećaj s Lewijevim tijelima (LBD), poželjno Parkinsonova bolest (PD), Parkinsonova bolest s demencijom (PDD) i demencija s Lewijevim tijelima (DLB), kao i višestruka atrofija sustava (MSA) ili neurodegeneracija tipa I s akumuliranjem željeza u mozgu (NBIA tipa I).
4. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se spoj spaja na farmaceutski prihvatljiv nosač, poželjno KLH (Keyhole Limpet Hemocyanin).
5. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se spoj formulira za intravenoznu, subkutanu, intradermalnu ili intramuskularnu primjenu.
6. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se spoj formulira s pomoćnim sredstvom, poželjno s aluminijevim hidroksidom.
7. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je spoj kao sastojak lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, najbolje od 100 ng do 100 μg.
8. Peptid, naznačen time, da taj peptid ima aminokiselinsku sekvencu odabranu iz sljedeće skupine:
CDQPVLPD, CDMPVLPD, CDSPVLPD, CDQPVLPDN, CDMPVLPDN, CDSPVLPDN, CHDRPVTPD, CDRPVTPD, CDVPVLPD, CDTPVYPD, CDTPVIPD, CHDRPVTPDN, CDRPVTPDN, CDVPVLPDN, CDTPVYPDN, CDQPVLPDG, CDMPVLPDG, CDSPVLPDG, CDHPVHPDS, CDMPVSPDR, CDRPVYPDI, CDHPVTPDR, CDTPVLPDS, CDMPVTPDT, CDAPVTPDT, CDSPVVPDN, CDLPVTPDR, CDSPVHPDT, CDAPVRPDS, CDMPVWPDG, CDRPVQPDR, CYDRPVQPDR, CDMPVDADN, DQPVLPDC i DMPVLPDC.
9. Peptid prema zahtjevu 8, naznačen time, da se peptid spaja na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
10. Farmaceutska formulacija, naznačena time, da sadrži najmanje jedan peptid prema zahtjevu 8 ili 9.
11. Farmaceutska formulacija prema zahtjevu 10, naznačena time, da se upotrebljava kao cjepivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0029708A AT506535B1 (de) | 2008-02-22 | 2008-02-22 | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
EP09712380.6A EP2334326B1 (en) | 2008-02-22 | 2009-02-23 | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders |
PCT/AT2009/000071 WO2009103105A2 (en) | 2008-02-22 | 2009-02-23 | Mimotope |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20151148T1 true HRP20151148T1 (hr) | 2015-12-18 |
Family
ID=40933571
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20151148TT HRP20151148T1 (hr) | 2008-02-22 | 2015-10-29 | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja |
HRP20181512TT HRP20181512T1 (hr) | 2008-02-22 | 2018-09-24 | Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181512TT HRP20181512T1 (hr) | 2008-02-22 | 2018-09-24 | Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja |
Country Status (20)
Country | Link |
---|---|
US (4) | US9724399B2 (hr) |
EP (3) | EP3388074B1 (hr) |
JP (4) | JP5804707B2 (hr) |
KR (1) | KR101627763B1 (hr) |
CN (4) | CN101969989B (hr) |
AT (1) | AT506535B1 (hr) |
AU (1) | AU2009217216B2 (hr) |
BR (1) | BRPI0908097A2 (hr) |
CA (1) | CA2716007C (hr) |
CY (2) | CY1116841T1 (hr) |
DK (2) | DK2946790T3 (hr) |
ES (3) | ES2550781T3 (hr) |
HK (2) | HK1214769A1 (hr) |
HR (2) | HRP20151148T1 (hr) |
HU (2) | HUE025963T2 (hr) |
LT (1) | LT2946790T (hr) |
PL (2) | PL2334326T3 (hr) |
PT (2) | PT2334326E (hr) |
SI (2) | SI2334326T1 (hr) |
WO (1) | WO2009103105A2 (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン,インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
US9533037B2 (en) | 2007-10-16 | 2017-01-03 | Declion Holdings Llc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
WO2009128948A1 (en) | 2008-04-17 | 2009-10-22 | Peptimmune, Inc. | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
SI2370466T1 (sl) | 2008-12-19 | 2015-11-30 | Biogen International Neuroscience Gmbh | Človeška avtoprotitelesa proti alfa-sinukleinu |
DK2723379T3 (en) * | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
PT2579042E (pt) | 2011-10-04 | 2014-09-09 | Affiris Ag | Método para detecção de anticorpos específicos para a numa amostra biológica. |
SG11201404321YA (en) * | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP3783020A1 (en) * | 2013-11-21 | 2021-02-24 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
NZ728041A (en) * | 2014-07-10 | 2023-01-27 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington’s disease |
US10857122B2 (en) * | 2015-03-09 | 2020-12-08 | Immune Modulation, Inc. | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases |
BR112018008697A2 (pt) * | 2015-11-03 | 2018-10-30 | Affiris Ag | método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação. |
CN116650617A (zh) * | 2016-06-29 | 2023-08-29 | 加利福尼亚大学董事会 | α-突触核蛋白聚集的基于结构的肽抑制剂 |
TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
US20230287050A1 (en) | 2020-08-04 | 2023-09-14 | Ac Immune Sa | Immunogenic Compounds |
TW202306966A (zh) * | 2021-06-18 | 2023-02-16 | 日商住友製藥股份有限公司 | 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物 |
WO2023152260A1 (en) | 2022-02-09 | 2023-08-17 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
WO2023161527A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
AT525943A2 (de) * | 2022-02-28 | 2023-09-15 | Tridem Bioscience Gmbh & Co Kg | Konjugat bestehend aus oder umfassend zumindest ein ß-Glucan oder ein Mannan |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170229A1 (en) * | 1999-02-25 | 2003-09-11 | Smithkline Beecham Biologicals S.A. | Vaccine |
US8106174B2 (en) * | 2000-05-08 | 2012-01-31 | Monsanto Technology Llc | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
US20070020625A1 (en) * | 2001-02-07 | 2007-01-25 | Eric Duchaud | Sequence of the photorhabdus luminescens strain tt01 genome and uses |
JP4863341B2 (ja) * | 2001-09-06 | 2012-01-25 | Meiji Seikaファルマ株式会社 | ヒラメラブドウイルス感染魚類用dnaワクチン |
CA2466841A1 (en) | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
GB0216972D0 (en) * | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US20070155771A1 (en) * | 2003-04-11 | 2007-07-05 | David Rubinsztein | Methods and means for treating protein conformational disorders |
EP1633189B1 (en) | 2003-05-19 | 2017-07-05 | Prothena Biosciences Limited | Truncated fragments of alpha-synuclein in lewy body disease |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
WO2004113535A1 (ja) | 2003-06-22 | 2004-12-29 | Koji Sode | 凝集抑制作用を有するシヌクレイン変異体 |
JP2008520589A (ja) * | 2004-11-17 | 2008-06-19 | ジョアン マクローリン, | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 |
CN101142482A (zh) * | 2005-02-25 | 2008-03-12 | 阿拉巴马大学董事会 | 蛋白错误折叠和聚集的调节因子及其使用方法 |
CA2598792A1 (en) * | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
MX2007014524A (es) * | 2005-05-18 | 2008-02-07 | Maxygen Inc | Polipeptidos desarrollados de interferon-alfa. |
US20090093405A1 (en) * | 2006-01-19 | 2009-04-09 | Ambrx, Inc. | Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity |
US20070197453A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
EP2091566A4 (en) * | 2006-11-24 | 2011-07-06 | Waratah Pharmaceuticals Inc | COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES |
PL2118300T3 (pl) * | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
US20120142902A1 (en) * | 2007-02-23 | 2012-06-07 | The Regents Of The University Of California | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
AT505574B1 (de) * | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
-
2008
- 2008-02-22 AT AT0029708A patent/AT506535B1/de not_active IP Right Cessation
-
2009
- 2009-02-23 KR KR1020107019372A patent/KR101627763B1/ko active IP Right Grant
- 2009-02-23 PL PL09712380T patent/PL2334326T3/pl unknown
- 2009-02-23 EP EP18173825.3A patent/EP3388074B1/en active Active
- 2009-02-23 CN CN200980105866.6A patent/CN101969989B/zh active Active
- 2009-02-23 SI SI200931295T patent/SI2334326T1/sl unknown
- 2009-02-23 DK DK15173612.1T patent/DK2946790T3/en active
- 2009-02-23 ES ES09712380.6T patent/ES2550781T3/es active Active
- 2009-02-23 US US12/918,077 patent/US9724399B2/en active Active
- 2009-02-23 JP JP2010547001A patent/JP5804707B2/ja active Active
- 2009-02-23 CN CN201510561387.2A patent/CN105250999B/zh active Active
- 2009-02-23 EP EP09712380.6A patent/EP2334326B1/en active Active
- 2009-02-23 DK DK09712380.6T patent/DK2334326T3/en active
- 2009-02-23 ES ES18173825T patent/ES2962346T3/es active Active
- 2009-02-23 PT PT97123806T patent/PT2334326E/pt unknown
- 2009-02-23 AU AU2009217216A patent/AU2009217216B2/en active Active
- 2009-02-23 HU HUE09712380A patent/HUE025963T2/en unknown
- 2009-02-23 SI SI200931880T patent/SI2946790T1/sl unknown
- 2009-02-23 HU HUE15173612A patent/HUE039860T2/hu unknown
- 2009-02-23 WO PCT/AT2009/000071 patent/WO2009103105A2/en active Application Filing
- 2009-02-23 ES ES15173612.1T patent/ES2688118T3/es active Active
- 2009-02-23 LT LTEP15173612.1T patent/LT2946790T/lt unknown
- 2009-02-23 PL PL15173612T patent/PL2946790T3/pl unknown
- 2009-02-23 BR BRPI0908097A patent/BRPI0908097A2/pt not_active Application Discontinuation
- 2009-02-23 CA CA2716007A patent/CA2716007C/en active Active
- 2009-02-23 CN CN202211233768.4A patent/CN116327905A/zh active Pending
- 2009-02-23 EP EP15173612.1A patent/EP2946790B1/en active Active
- 2009-02-23 CN CN201710228381.2A patent/CN107261133A/zh active Pending
- 2009-02-23 PT PT15173612T patent/PT2946790T/pt unknown
-
2014
- 2014-05-23 JP JP2014107332A patent/JP2014177483A/ja active Pending
-
2015
- 2015-10-21 CY CY20151100940T patent/CY1116841T1/el unknown
- 2015-10-29 HR HRP20151148TT patent/HRP20151148T1/hr unknown
-
2016
- 2016-03-11 HK HK16102825.9A patent/HK1214769A1/zh unknown
- 2016-07-07 JP JP2016135134A patent/JP6410764B2/ja active Active
- 2016-12-12 US US15/375,234 patent/US10517935B2/en active Active
-
2018
- 2018-04-13 HK HK18104829.9A patent/HK1245136A1/zh unknown
- 2018-06-12 JP JP2018111725A patent/JP2018154650A/ja active Pending
- 2018-09-24 HR HRP20181512TT patent/HRP20181512T1/hr unknown
- 2018-09-28 CY CY181101007T patent/CY1120709T1/el unknown
-
2019
- 2019-12-11 US US16/709,999 patent/US11534484B2/en active Active
-
2022
- 2022-11-21 US US18/057,273 patent/US20230201320A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
HRP20160594T1 (hr) | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima | |
AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
RU2011100125A (ru) | Соединения для лечения амилоидозов | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
PH12019501215A1 (en) | Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid | |
BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
AR088161A1 (es) | Analogos de glucagon | |
CL2011001924A1 (es) | Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor. | |
IL270395B (en) | A therapeutic agent for dementia that combines a pyrozoloquinoline derivative and donepezil | |
WO2001087284A3 (en) | Aldosterone antagonist composition for release during aldosterone acrophase | |
JP2015537002A5 (hr) | ||
WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
HRP20130892T1 (hr) | Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije | |
JP2016500682A5 (hr) | ||
RU2014114506A (ru) | Вакцина | |
ECSP088654A (es) | Derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo como inhibidores de la catepsina k y s | |
RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
ES2307760T3 (es) | Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. | |
AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso |